Hydra Biosciences, Inc.

Boehringer Ingelheim International Gmbh

Eli Lilly and Company

Kamari Pharma Ltd.

Amgen Inc.

Cubist Pharmaceuticals, Incorporated

Mitobridge, Inc.

Alantos Pharmaceuticals Holding, Inc.

Atlantos Pharmaceuticals Holding, Inc.

Merck Sharp + Dohme Corp.

Xinyuan Edward Wu

Bertrand Leo Chenard

Spencer David Kimball

Michael Robert Turner

Thierry Bouyssou

Christopher Ronald Sarko

Lana Louise Smith Keenan

Michael Dennis Lowe

Simon Surprenant

Arthur G Taveras

Ping Chen

Niklas Heine

Hongbo Deng

Christian Gege

Hidenori Takahashi

Hossein Razavi

Christoph Steeneck

Ding Zhou

Dirk Gottschling

Bert Nolte

Irving Sucholeiki

Matthias Schneider

Shaoping Peng

Brian M Gallagher, Jr

Blaise S Lippa

Matthias Hochgürtel

Torsten Arndt

Tim Feuerstein

Heiko Kroth

Frank Richter

Harald Bluhm

Ralf Biesinger

Nili Claudia Schutz

Dov Terkieltaub

Arthur F Kluge

Chester A Metcalf, Iii

Bharat Lagu

Richard A Earl

Dong Zou

Steven Richard Brunette

Yu Gui Gu

Iwona Wrona

Matthew Frank Baevsky

Jared Peters Smit

Qingyi Li

Christopher Matthew Liu

Sanjita Sasmal

Jianwen Cui

Eric Bell

Carine Chevrier

Margaret Biddle

Michael Essers

Takashi Ogiyama

Andrew J Jackson

Joshua Van Veldhuizen

Guohua Liang

Lisa Mcqueen

Paul Nicklin

Brett A Cowans

Michael Bosies

Qingy Li

Dominic Ryan

Michael Essors

Richard Alan Earl

Steven Brunette

Brett Cowans

Chester A Iii Metcalf

Bertand L Chenard

Yugui Gu

M Dominic Ryan

Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R, R, R, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.

Compounds and compositions for use in treating skin disorders

The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Inhibitors of TRPC6

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein Rto R, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Inhibiting the transient receptor potential al ion channel

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

HMOX1 inducers

Inhibiting the transient receptor potential A1 ion channel

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Compounds and compositions for treating disorders related to TRPA1 are described herein.

Compounds useful for treating disorders related to TRPA1

This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain.

Inhibiting transient receptor potential ion channel TRPA1

Compounds useful for treating injuries from warfare agents

Growing community of inventors

Chestnut Hill, MA, United States of America

Xinyuan Edward Wu